PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Managing Cytopenic Myelofibrosis: New and Emerging Therapies and Who May Benefit
Visit https://www.peervoice.com/GCF860 to view the entire programme with slides. After completing “Managing Cytopenic Myelofibrosis: New and Emerging Therapies and Who May Benefit”, participants will be able to: Differentiate between the Janus kinase (JAK) inhibitors, including emerging therapies that could be used for cytopenic myelofibrosis; Formulate individualized treatment plans for patients with cytopenic myelofibrosis, considering disease- and patient-specific factors; and Evaluate how current and emerging therapeutic options may fit into the treatment paradigm for patients with cytopenic myelofibrosis.